Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR ‐1210), a novel anti‐PD‐1 antibody

ConclusionsSerum LDH, which is readily available in routine clinical practice, is a potential marker for response and a powerful independent factor for survival in advanced ESCC patients treated with anti ‐PD‐1 therapy.

Source: Thoracic Cancer - April 23, 2019 Category: Cancer & Oncology Authors: Xi Wang, Bo Zhang, Xuelian Chen, Hongnan Mo, Dawei Wu, Bo Lan, Qun Li, Binghe Xu, Jing Huang Tags: ORIGINAL ARTICLE Source Type: research